7 unknown. 7 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Unknown 7 |
| Phase 1 | 3 | Unknown 3 |
Follow Myelofibrosis: new trials by email Literature Review of Myelofibrosis trials Research Report on Myelofibrosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Bomedemstat (IMG-7289) Plus Ruxolitinib for Myelofibrosis Bomedemstat - Myelofibrosis | Phase 2 | Unknown | The University of Hong Kong | 40 | 2022-12-01 | 2023-05-23 |
| Ropeginterferon Alfa 2b for Early Myelofibrosis Ropeginterferon alfa-2b - Primary Myelofibrosis, Prefibrotic Stage, Myelofibrosis | Phase 2 | Unknown | The University of Hong Kong | 50 | 2021-09-01 | 2022-10-06 |
| Haplo-identical Transplantation in Patients With Myelofibrosis - A Phase 2 Prospective Multicentric Prospective Study Allogenic transplantation transplantation - Myelofibrosis | Phase 2 | Unknown | Assistance Publique - Hôpitaux de Paris | 28 | 2021-01-30 | 2021-01-28 |
| An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post ET-MF) Who Have a Suboptimal Response to Ruxolitinib KRT-232, Ruxolitinib - Myelofibrosis | Phase 1 / Phase 2 | Unknown | Kartos Therapeutics, Inc. | 36 | 2021-01-28 | 2022-05-09 |
| KRT-232 in Combination With TL-895 for the Treatment of R/R MF and KRT-232 for the Treatment of JAKi Intolerant MF KRT-232, TL-895 - Myelofibrosis, Post-PV MF | Phase 1 / Phase 2 | Unknown | Kartos Therapeutics, Inc. | 116 | 2020-11-17 | 2022-05-09 |
| Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis TL-895, Placebo - Myelofibrosis, Indolent Systemic Mastocytosis | Phase 2 | Unknown | Telios Pharma, Inc. | 121 | 2020-10-22 | 2024-05-10 |
| CEP-701 (Lestaurtinib) in Myelofibrosis CEP-701 (Lestaurtinib) - Myelofibrosis, Essential Thrombocythemia | Phase 1 / Phase 2 | Unknown | Ronald Hoffman | 60 | 2008-04-01 | 2014-11-26 |
Primary Myelofibrosis (7) · Mastocytosis, Systemic (1) · Polycythemia Vera (1) · Thrombocythemia, Essential (1)
Bone Marrow Diseases (7) · Hematologic Diseases (7) · Hemic and Lymphatic Diseases (7) · Myeloproliferative Disorders (7) · Neoplasms (2) · Blood Coagulation Disorders (1) · Blood Platelet Disorders (1) · Bone Marrow Neoplasms (1) · Hematologic Neoplasms (1) · Hemorrhagic Disorders (1) · Immune System Diseases (1) · Mast Cell Activation Disorders (1) · Mastocytosis (1) · Neoplasms by Histologic Type (1) · Neoplasms by Site (1)
navtemadlin; 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid (2) · bomedemstat (1) · lestaurtinib (1) · ruxolitinib (1)
Kartos Therapeutics, Inc. (2) · The University of Hong Kong (2) · Assistance Publique - Hôpitaux de Paris (1) · Ronald Hoffman (1) · Telios Pharma, Inc. (1)
United States (4) · Bulgaria (3) · France (3) · Germany (3) · Italy (3) · Poland (3) · Spain (3) · Australia (2) · Hong Kong (2) · Hungary (2) · Austria (1) · Belgium (1) · Brazil (1) · Israel (1) · Serbia (1)
Harinder Gill, MD (1) · Ronald Hoffman, MD (1)
PMID 25563429, PMID 41758981, PMID 41875235
P01CA108671 (1)